Saturday 17 October 2026 Export ANNX’s income statement to Excel — free account

Annexon, Inc.

In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.41 0.19 −5.28%

Follow ANNX

Alert me

Market cap: $682.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 12.39

Total sells 0.31

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	3	—	—	1	1	2	—	—	—	1	—
Sell	—	—	—	5	5	—	—	—	—	—	—	—

Insider Ownership 17.95%

Capital & Financial Ratios $m

Market Cap 682.49

Revenue —

Net Income (202.67)

Free Cash Flow (193.23)

Net Debt (209.24)

Current Ratio 5.53

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.68

Past 5Y EPS Growth —

This Y EPS Growth 21.78%

Next Y EPS Growth 5.20%

Next Y revenue growth —

Next 5Y EPS Growth 44.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 85.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	260	312	238	209
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	264	316	242	213

	2023	2024	2025	Q'26
Payables	5	10	15	16
ST’ Debt	—	—	—	—
Other	—	—	—	—
	18	31	43	38

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(9.27%)	(2.90%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(47)	(48)	—	—	—
’25	(50)	(38)	(52)	(46)	(186)
’24	(28)	(22)	(32)	(36)	(118)
’23	(33)	(36)	(28)	(23)	(121)
’22	(30)	(28)	(31)	(27)	(116)
’21	(23)	(25)	(30)	(28)	(106)
’20	(10)	(10)	(14)	(19)	(53)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(47)	(48)	—	—	—
’25	(50)	(38)	(52)	(46)	(186)
’24	(28)	(22)	(32)	(36)	(118)
’23	(33)	(36)	(28)	(23)	(121)
’22	(36)	(29)	(31)	(27)	(123)
’21	(23)	(25)	(30)	(29)	(108)
’20	(10)	(10)	(14)	(19)	(54)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.23)	(0.28)	—	—	—
’25	(0.37)	(0.34)	(0.37)	(0.28)	(1.34)
’24	(0.21)	(0.23)	(0.25)	(0.33)	(1.01)
’23	(0.52)	(0.47)	(0.43)	(0.36)	(1.77)
’22	(0.92)	(0.96)	(0.51)	(0.48)	(2.60)
’21	(0.68)	(0.82)	(0.93)	(0.97)	(3.40)
’20	(28.45)	(28.87)	(0.77)	(0.61)	(4.15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	15.33	11.34	2.06	1.57	3.86	1.29	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	31.94	38.01	11.95	7.65	8.40	5.66
People
People	Employees	—	—	—	30	48	61	80	71	100	96
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	(19)	(18)	(37)	(63)	(130)	(142)	(134)	(138)	(207)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(18)	(37)	(63)	(130)	(142)	(134)	(138)	(207)
	Depreciation	—	0	0	0	1	2	2	2	2	2
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(0.49)	(45.45)	(85.78)	(4.15)	(3.40)	(2.60)	(1.77)	(1.01)	(1.34)
	Cash flow	—	(0.50)	(42.69)	(65.42)	(3.13)	(2.77)	(2.13)	(1.60)	(0.86)	(1.20)
	Capex	—	0.00	(0.04)	(0.62)	(0.03)	(0.04)	(0.12)	0.00	0.00	0.00
	Free cash flow	—	(0.50)	(42.73)	(66.03)	(3.16)	(2.81)	(2.25)	(1.60)	(0.86)	(1.20)
	Book value	—	(1.21)	(159.43)	(231.73)	20.30	6.05	4.23	3.31	2.13	1.36
	Shares, m	—	38	0	0	17	38	55	76	137	155
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(19)	(17)	(28)	(53)	(106)	(116)	(121)	(118)	(186)
	Capex	—	(1)	0	0	0	(2)	(7)	0	0	0
	Free cash flow	—	(19)	(17)	(29)	(54)	(108)	(123)	(121)	(118)	(186)
Balance, $m
Balance, $m	Working capital	—	2	42	40	343	226	226	246	286	200
	Total debt	—	49	107	—	—	35	33	—	—	—
	Net debt	—	46	(44)	(44)	(351)	(243)	(243)	(260)	(312)	(238)
	Shareholders’ equity	—	(46)	(64)	(100)	344	232	231	251	293	212
Returns, %
Returns, %	ROA	—	(67.16)	(76.76)	(78.08)	(34.66)	(40.54)	(49.62)	(46.07)	(42.67)	(66.45)
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	34.04	33.47	46.49	(57.69)	(45.24)	(61.30)	(55.73)	(50.84)	(82.63)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$710.1M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
OABI OmniAb, Inc.	$687.7M	— (loss-making)	— (loss-making)	+244.24% (above 0%: growing)	n/m	+211.16% (above 0%: growing)	95.45%	(49.47%)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%
MDXG MiMedx Group, Inc	$682.2M	111×	— (loss-making)	−34.73% (below 0%: shrinking)	n/m	−174.83% (below 0%: shrinking)	68.96%	(28.69%)	Compare
CADL Candel Therapeutics, Inc.	$681.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−93.35% (below 0%: shrinking)	0.00%	0.00%	Compare
PHAR Pharming Group N.V. Sponsored ADR	$681.6M	62.4×	— (loss-making)	−3.22% (below 0%: shrinking)	−57.14% (below 0%: shrinking)	−183.87% (below 0%: shrinking)	83.92%	1.44%	Compare
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)	Compare
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$681.7M	—	—	−2.12%	—	−74.80%	68.96%	0.00%

All 614 Biotechnology stocks →

Annexon, Inc. (ANNX) key facts

Concern: Annexon, Inc. reported a net loss of $206.7 million, or a loss of $1.34 per share, for fiscal 2025.
Annexon, Inc. (ANNX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ANNX traded at $3.41, a market capitalization of $682.5 million.
Return on equity was −82.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.